FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a method for producing a model immortalized cell line containing a surface-exposed transmembrane-anchored form of a B-cell receptor (BCR) of non-Hodgkin's lymphoma (NHL) human lymphocytes in single-stranded antibody (scFv) format, fused with constant domain of human immunoglobulin IgG1 (Fc) and transmembrane anchor, to develop personalized approaches to therapy of human lymphoproliferative diseases.
EFFECT: disclosed is a method of producing a model immortalized cell line containing a reconstructed B-cell receptor of non-Hodgkin lymphomas.
1 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| TEST SYSTEM FOR ANALYSING FUNCTIONAL ACTIVITY OF ANTIBODIES AGAINST PD-1 AND ANTIBODIES AGAINST PD-L1 | 2019 |
|
RU2731896C1 |
| CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2684713C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| GENETIC CONSTRUCT CODING STRUCTURE OF T-CELL CHIMERIC RECEPTOR BASED ON SINGLE-CHAIN VHH ANTIBODIES SPECIFIC TO TUMOUR RECEPTOR CD47 FOR THE TARGETED IMMUNOTHERAPY OF MALIGNANT GROWTHS | 2017 |
|
RU2707535C2 |
| USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS | 2009 |
|
RU2589704C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| UNIVERSAL BIOSENSOR SYSTEM FOR ANALYTE DETECTION | 2017 |
|
RU2737943C1 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
